|
⚲
|
| Keyboard |
| Baker Bros Advisors LP
✚
|
|
|---|---|
| CRD # | 158149 |
| SEC # | 801-73446 |
| CIK # | 0001263508 |
| AUM | 28.15 B (2026-03-27) |
| Employees | 60 (28% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-339-5600 |
| Address | 860 Washington Street, 3rd Floor New York, NY 10014 |
| Source | [IAPD] [EDGAR] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/27/2026) [Brochure] |
|---|
Item 5 – Fees and Compensation A. The Funds offer interests only to “qualified purchasers” within the meaning of Section 2(a)(51) of the Investment Company Act of 1940, as amended. Admission to the Funds is not open to the general public. Investors and prospective Investors should refer to the limited partnership agreement or other governing document of the appropriate Fund for a detailed description of the fees. The Funds generally compensate BBA with a management fee (the “Management Fee”) based on either (1) committed capital and profits or (2) net assets, with the limited partnership agreement or other governing document of the appropriate Fund setting forth which approach is utilized. Where a Management Fee is based on committed capital and profits, the Management Fee is calculated with distributions deducted first from profits. In addition, performance-based compensation, based on the net profits allocated to each Investor and calculated on a high watermark basis (the “Incentive Allocation”), calculation described in more detail in the Fund documents, is allocated to the general partners (which are affiliates of BBA) of the respective Funds (the “General Partners”). The amounts of the Management Fee and the Incentive Allocation vary among the Funds. BBA from time to time makes discretionary downward adjustments to the Management Fee for all similarly situated limited partners but may discontinue such practice at any time. Fee arrangements for certain Funds were determined at inception of those Funds or pursuant to their Limited Partnership Agreements, and such arrangements apply to all Investors in each such Fund, other than BBA related persons. The General Partner waives the Management Fee and Incentive Allocations for Investors that are partners, employees, relatives or affiliates of the General Partner or the Investment Manager. Otherwise, the Management Fee and Incentive Allocation are generally not negotiable. Investors and prospective Investors should refer to the Funds’ limited partnership agreements and other governing documents for more detailed information regarding how BBA is compensated for its advisory services. The information contained herein is a summary only and is qualified in its entirety by such documents. B. BBA deducts fees directly from the Funds’ assets. Investors do not have the ability to choose to be billed directly for fees. Management Fees are generally calculated monthly or quarterly in advance as specified in the relevant governing document for each Fund. The Incentive Allocation (if applicable) is generally made on the last business day of each calendar year, or at the time of withdrawal by an Investor subject to certain exceptions detailed in the limited partnership agreement of each Fund. Investors and prospective Investors should refer to the Funds’ limited partnership agreements and other governing documents for more detailed information regarding how BBA is compensated for its advisory services. The information contained herein is a summary only and is qualified in its entirety by such documents. C. In addition to the compensation described above, each Fund generally bears certain expenses, which include, but are not limited to: (i) investment-related expenses (whether or not any such investment is consummated), (including the costs of consultants and experts sourced both directly and through expert networks; costs of all research, including primary research, such as direct surveys; attendance at industry conferences and events (including admission fees); travel, including but not limited to airfare at various rates which will include fully refundable airline tickets for first-class, business class, coach and charter (which will in some cases, include all of BBA’s investing professionals) as well as higher-end hotels and restaurants and inflight internet expenses; brokerage and prime brokerage fees; stock loan fees; and fees embedded in money market funds held by the Funds); (ii) fees and other expenses related to all regulatory filings, including legal, filing, and other costs related to regulatory filings, including but not limited to Form 13F and Form 13H filings, Form 3 and Form 4 filings, Schedule 13D and 13G filings, Form N-PX filings and filings under the Hart-Scott-Rodino Antitrust Improvements Act of 1976; (iii) third-party legal, governance, accounting, audit and tax preparation, appraisal, custodial and registration expenses, including third-party fund administration fees; (iv) fees related to proxy voting services; (v) fees related to class action services; (vi) offering expenses; (vii) liquidation expenses; (viii) sales or other taxes, fees or government charges; (ix) expenses of members of the advisory boards (with respect to certain Funds); (x) expenses relating to litigation and threatened litigation involving the applicable Fund, including permitted indemnification expenses; (xi) premiums for liability or other insurance for the benefit of the Fund, its General Partner, BBA, certain of BBA’s affiliates, members of the Fund’s advisory board (if applicable) and any of their respective partners, members, stockholders, officers, directors, employees, agents or affiliates in connection with the activities of the Fund1; (xii) profits disgorged by a Fund under Section 16 of the Securities Exchange Act of 1934; and (xiii) other similar expenses related to such Fund and any extraordinary expenses. For a Fund that is part of a master-feeder structure, each feeder fund will indirectly bear the administrative and other expenses of the master fund pro rata based on its interest in the master fund. Each Fund also generally bears all costs and expenses incurred in connection with its formation ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/27/2026) [Brochure] |
|---|
Item 7 – Types of Clients BBA provides investment advisory services to pooled investment vehicles operating as private investment funds. Investment in these Funds is limited to investors that meet the eligibility qualifications of both (i) “accredited investors” within the meaning of Regulation D of the Securities Act of 1933, as amended (“Accredited Investors”) and (ii) “qualified purchasers” within the meaning of Section 2(a)(51) of the Investment Company Act of 1940, as amended. The majority of the Investors in the Funds are institutional investors, primarily foundations and endowments. In general, the minimum initial investment amount in Baker Brothers Life Sciences, L.P. or its feeder, HCIF Offshore LP is $20,000,000 (aggregated by relationship); however, this is subject to the discretion of the General Partner of each Fund, and this discretion has been delegated to BBA. 667. L.P. is not open to new investors. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Incyte Corp | 2.9 | ||
| BeiGene Ltd | 2.6 | ||
| Insmed Inc | 1.2 | ||
| Synta Pharmaceuticals Corp | 1.1 | ||
| Acadia Pharmaceuticals Inc | 1.0 | ||
| Revolution Medicines Inc | 0.9 | ||
| Celcuity Inc | 0.9 | ||
| Kodiak Sciences Inc | 0.8 | ||
| Kymera Therapeutics Inc | 0.7 | ||
| Summit Therapeutics PLC | 0.7 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | 14159 LP | 2012-02-13 | 17.0 M | |
| HF | 667 LP | 2012-02-13 | 2,337.7 M | |
| HF | Baker Biotech Fund II A LP | 2012-02-13 | 9.4 M | |
| HF | Baker Bros Investments II LP | 2012-02-13 | 1.2 M | |
| HF | Baker Bros Investments LP | 2012-02-13 | 9.8 M | |
| HF | Baker Brothers Life Sciences LP | [2012-02-13] | 25.81 B | |
| Filed 2025-10-14 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Baker/Tisch Investments LP | 2012-02-13 | 11.0 M | |
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 2 | 28.1 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 2 | 28.1 |
| By Discretionary | ||
| Discretionary | 2 | 28.1 |
| Non-Discretionary | 0 | 0.0 |
| Total | 2 | 28.1 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 28.1 | |
| Total | 2 | 28.1 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Felix Baker | Executive Officer | 20 | 2 | |
| Julian Baker | Executive Officer | 9 | 2 | |
| Baker Brothers Life Sciences Capital LP | Executive Officer | 8 | 2 | |
| Baker Brothers Life Sciences Capital GP LLC | Executive Officer | 6 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001263508] | |
| 3 | [0001263508] | |
| 4 | [0001263508] | |
| 5 | [0001263508] | |
| SC 13D | [0001263508] | |
| SC 13G | [0001263508] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $11.0B |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300QYZVDO3190ER85 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
DBV Technologies SA DBVT
BS Warrant · derivative
|
2026-01-12 | Option exercise | 2,299,656 | $0.00 | |
|
DBV Technologies SA DBVT
BS Warrant · derivative
|
2026-01-12 | Option exercise | 25,005,240 | $0.00 | |
|
DBV Technologies SA DBVT
Second Pre-Funded Warrant · derivative
|
2026-01-12 | Option exercise | 2,299,656 | $0.00 | |
|
DBV Technologies SA DBVT
Second Pre-Funded Warrant · derivative
|
2026-01-12 | Option exercise | 25,005,240 | $0.00 | |
|
Bicycle Therapeutics PLC BCYC
Share Option (Right to Buy) · derivative
|
2026-01-02 | Grant | 38,000 | $0.00 | |
|
Bicycle Therapeutics PLC BCYC
Share Option (Right to Buy) · derivative
|
2026-01-02 | Grant | 38,000 | $0.00 | |
|
Bicycle Therapeutics PLC BCYC
American Depositary Shares
|
2026-01-02 | Grant | 19,000 | $0.00 | |
|
Bicycle Therapeutics PLC BCYC
American Depositary Shares
|
2026-01-02 | Grant | 19,000 | $0.00 | |
|
Incyte Corp INCY
Common Stock
|
2025-12-31 | Grant | 328 | $0.00 | |
|
Incyte Corp INCY
Common Stock
|
2025-12-31 | Grant | 328 | $0.00 | |
|
Kodiak Sciences Inc KOD
Common Stock
|
2025-12-18 | Buy | 2,391,268 | $23.00 | 54,999,164 |
|
Kodiak Sciences Inc KOD
Common Stock
|
2025-12-18 | Buy | 217,428 | $23.00 | 5,000,844 |
|
Kymera Therapeutics Inc KYMR
Common Stock
|
2025-12-11 | Buy | 1,838,621 | $86.00 | 158,121,406 |
|
Kymera Therapeutics Inc KYMR
Common Stock
|
2025-12-11 | Buy | 167,192 | $86.00 | 14,378,512 |
|
Denali Therapeutics Inc DNLI
$0.01 Prefunded Warrants · derivative
|
2025-12-11 | Buy | 190,523 | $17.49 | 3,332,247 |
|
Denali Therapeutics Inc DNLI
$0.01 Prefunded Warrants · derivative
|
2025-12-11 | Buy | 2,095,191 | $17.49 | 36,644,891 |
|
Entrada Therapeutics Inc TRDA
Common Stock
|
2025-11-20 | Buy | 1,213 | $9.07 | 11,002 |
|
Entrada Therapeutics Inc TRDA
Common Stock
|
2025-11-20 | Buy | 1,186 | $9.07 | 10,757 |
|
Entrada Therapeutics Inc TRDA
Common Stock
|
2025-11-20 | Buy | 13,386 | $9.07 | 121,411 |
|
Entrada Therapeutics Inc TRDA
Common Stock
|
2025-11-20 | Buy | 13,082 | $9.07 | 118,654 |
| showing 20 of 200 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Gotham Asset Management LLC
✚
|
NY | 30.03 B |
|
Voleon Capital Management LP
✚
|
CA | 29.38 B |
|
Quadrature US Inc
✚
|
NY | 28.80 B |
|
Axiom Investors LLC
✚
|
CT | 28.06 B |
|
Jacobs Levy Equity Management Inc
✚
|
NJ | 28.01 B |
|
Research Affiliates LLC
✚
|
CA | 27.84 B |
|
Anchorage Capital Advisors LP
✚
|
NY | 27.83 B |
|
Kirkoswald Asset Management LLC
✚
|
NY | 27.16 B |
|
Aristotle Pacific Capital LLC
✚
|
CA | 26.76 B |
|
CFI Partners LLC
✚
|
IL | 26.31 B |